Researchers included 253 Swiss women with uncomplicated lower UTIs in the study. They randomly assigned 133 women to receive symptomatic treatment with the diclofenac, an NSAID, and 120 women received antibiotic treatment with norfloxacin. The primary outcome was symptom resolution at day three.
The study shows 54 percent of women assigned to diclofenac and 80 percent assigned to norfloxacin experienced symptom resolution at day three. The median time until resolution of symptoms was four days in the diclofenac group and two days in the norfloxacin group. Additionally, 62 percent women in the diclofenac group and 98 percent in the norfloxacin group used antibiotics up to day 30.
Thus, diclofenac is inferior to norfloxacin in reducing UTI symptoms, “even though it reduces antibiotic use in women with uncomplicated lower UTI,” study authors concluded.
More articles on healthcare quality:
Surgeons use stem cells to replace 80% of child’s damaged skin
Emory study: Neurosurgeons can run 2 operations at once without endangering patients
85% of patients, providers say healthcare costs are disproportionate to quality
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
